Resolution Therapeutics: Paul Sekhri

Paul Sekhri

Edinburgh-based Resolution Therapeutics, a Syncona-backed clinical-stage biopharmaceutical company focused on the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, has appointed Paul Sekhri as chair, replacing Lisa Bright.

Sekhri has more than 35 years’ experience in the life sciences industry, including leading business development and strategy in major pharmaceutical and biotechnology companies, with a record of partnering, M&A and financing.

He is president and chief executive of vTv Therapeutics. Before that, he was president and chief executive of eGenesis and Lycera Corp. Prior to that, he held positions of increasing responsibility at Sanofi, Teva Pharmaceutical Industries, TPG Biotech, Cerimon Pharmaceuticals, Ariad Pharmaceuticals, and Novartis.

Amir Hefni, chief executive of Resolution said: “Paul brings a wealth of experience leading top-tier companies to develop breakthrough medicines, including novel treatments for patients with autoimmune disease. The team and I look forward to working with Paul to bring novel macrophage therapies… to patients in need.

“On behalf of the board of directors, I would also like to thank Lisa Bright for her impactful contributions as chair of Resolution over the last four years. Her vision and leadership have been instrumental in driving our strategic initiatives, fostering a culture of scientific excellence and getting Resolution to clinical stage. We wish her all the best.”

Edward Hodgkin, managing partner of Syncona Investment Management and non-executive director of Resolution, added: “Sekhri… brings a demonstrable track record in supporting companies through the development cycle and will act as a valuable sounding board for the company’s growing executive team.”

Sekhri commented, “I am delighted to join Resolution at such an exciting time as it prepares to enter the clinic with [new product] RTX001 and expand pipeline efforts into new indications where significant unmet patient need exists. I look forward to collaborating with Amir, the entire Resolution team and supporting the company as it expands its leadership in macrophage therapy.”

Join our mailing list

Stay up to date with all our events, awards and publications.

Information you provide us with will be kept private at all times, and will be used for communication and research purpose only.